SCHEMBL3974099

SCHEMBL3974099

NN1C(=O)CC(=O)NC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.39
MEN1 O00255 12/20 0.39
KMT2A Q03164 12/20 0.39
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 6/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
ALOX12 P18054 2/20 0.35
ALDH1A1 P00352 3/20 0.34
POLB P06746 2/20 0.34
HBB P68871 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
PKM P14618 1/20 0.34
CYP2C19 P33261 1/20 0.34
PSMD14 O00487 1/20 0.34
MMP2 P08253 1/20 0.34
DNMT1 P26358 1/20 0.34
APEX1 P27695 1/20 0.34
PTPN7 P35236 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239780 0.68 MEN1 (0.39) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL9580702 0.68 MEN1 (0.41) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL18656903 0.68 MAPT (0.39) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL1263340 0.68 CRBN (0.44) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL11471808 0.67 MEN1 (0.35) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL11049824 0.67 MAPT (0.42) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL11674859 0.66 MAPT (0.51) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL1509853 0.65
SCHEMBL11335800 0.65 MAPT (0.37) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL15411913 0.65 MAPT (0.37) MAPTMEN1KMT2ALMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102858906-A Scale inhibitor CLARIANT INT LTD 2013-01-02 CN claimed
CN-119019691-A Fluoropyridinium polychlorinated amine bactericidal polymer and preparation method and application thereof 山东科技大学 2024-11-26 CN disclosed
CN-114173920-B Polymeric adsorbent for aldehyde and preparation method thereof 3M创新有限公司 2024-09-03 CN disclosed
CN-111818995-B Urea impregnated zeolite adsorbent and method of making same 3M创新有限公司 2024-01-26 CN disclosed
CN-102858906-A Scale inhibitor CLARIANT INT LTD 2013-01-02 CN disclosed
CN-1795166-B (Meth)Acrylic ester compound and use thereof MITSUI CHEMICALS INC 2010-05-05 CN disclosed
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
CN-1795166-A (Meth)Acrylic ester compound and use thereof MITSUI CHEMICALS INC (JP) 2006-06-28 CN disclosed
US-20030229084-A1 Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY 2003-12-11 US disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed
CN-1209123-A New barbituric acid derivatives, processes for their prodn. and pharmaceutical agent contg. same BOEHRINGER MANNHEIM GMBH (DE) 1999-02-24 CN disclosed
US-5213972-A Production of thymidine and deoxyuridine, intermediates for AZT CHEMGEN CORPORATION (US) 1993-05-25 US disclosed
EP-0504279-A4 FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES 1993-02-17 EP disclosed
EP-0504279-A1 FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. CHEMGEN CORP (US) 1992-09-23 EP disclosed
WO-1991009130-A1 FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES CHEMGEN CORPORATION (US) 1991-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 MAPT 2040/4885MEN1 2102/4885KMT2A 3445/4885
US-20030229084-A1 Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases TNF, MMP3, TIMP3 MAPT 2045/4885MEN1 1984/4885KMT2A 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.